Fotios Asimakopoulos

Title(s)Associate Professor In Residence, Medicine
SchoolHealth Sciences
Address9500 Gilman Drive #0960
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Cambridge, Cambridge UKMD PhD01/1997Medicine, Hematology
    Hebrew University of Jerusalem, Jerusalem IsraelGolda Meir Fellow06/1999Hematology
    BWH, Harvard Medical School, Boston MAResidency06/2001Internal Medicine
    Memorial Sloan-Kettering Cancer Center, New York, NYFellowship06/2009Medical Oncology
    ABIM Board CertificationMedical Oncology

    Collapse Overview 
    Collapse Overview
    Our lab focuses on multiple myeloma, the second most common blood cancer. Myeloma is a growing problem in the ageing population and despite great advances in therapy in the last 15-20 years, it remains incurable for the vast majority of patients. Despite effective modern and more traditional treatment approaches, almost all patients will see their disease come back at some point in their course. For many of our patients myeloma can become a “chronic condition”: unfortunately however, the myeloma cancer cells tend to evolve more aggressive and drug-resistant with time, and when they come back, they often come back with vengeance. We are working towards the goal of making myeloma a problem that most patients can overcome and conquer for good.

    Collapse Research 
    Collapse Research Activities and Funding
    Tumor matrix remodeling in anti-myeloma immunity and immunotherapy
    NIH R01CA252937Jul 1, 2020 - Jun 30, 2025
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood. 2021 01 07; 137(1):61-74. Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen J, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F, Zhang J. PMID: 32640012.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    2. Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity. J Histochem Cytochem. 2020 12; 68(12):871-885. Papadas A, Arauz G, Cicala A, Wiesner J, Asimakopoulos F. PMID: 32623942.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    3. Versican in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1272:55-72. Papadas A, Asimakopoulos F. PMID: 32845502.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    4. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma. 2019 10; 60(10):2558-2562. Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F. PMID: 30845856.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    5. TIGIT checkpoint inhibition for myeloma. Blood. 2018 10 18; 132(16):1629-1630. Asimakopoulos F. PMID: 30337318.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    6. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer. 2018 07 03; 6(1):65. Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F. PMID: 29970158.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    7. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01; 4(3):343-350. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. PMID: 29302684.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    8. Mechanisms of Resistance in Multiple Myeloma. Handb Exp Pharmacol. 2018; 249:251-288. Papadas A, Asimakopoulos F. PMID: 28315070.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    9. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. J Biol Chem. 2018 02 16; 293(7):2452-2465. Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. PMID: 29279332.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    10. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol. 2017 08; 102(2):265-275. Asimakopoulos F, Hope C, Johnson MG, Pagenkopf A, Gromek K, Nagel B. PMID: 28254840.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    11. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016 08 04; 128(5):680-5. Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F. PMID: 27259980.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    12. Deploying myeloid cells against myeloma. Oncoimmunology. 2016 Mar; 5(3):e1090076. Jensen JL, Hope C, Asimakopoulos F. PMID: 27141348.
      View in: PubMed   Mentions:
    13. Single-molecule analysis reveals widespread structural variation in multiple myeloma. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7689-94. Gupta A, Place M, Goldstein S, Sarkar D, Zhou S, Potamousis K, Kim J, Flanagan C, Li Y, Newton MA, Callander NS, Hematti P, Bresnick EH, Ma J, Asimakopoulos F, Schwartz DC. PMID: 26056298.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    14. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb). 2015 Jun; 7(6):643-54. Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. PMID: 25998180.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    15. Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res. 2015 Aug; 3(8):881-90. Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F. PMID: 25941352.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    16. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct; 74(4):875-82. Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. PMID: 25168296.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    17. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014 May 22; 123(21):3305-15. Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F. PMID: 24723682.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    18. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma. 2013 Oct; 54(10):2112-21. Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P. PMID: 23432691.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    19. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013 Mar; 160(6):779-84. Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, Maroulakou I, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F. PMID: 23252623.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    20. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012 Aug; 158(3):336-46. Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P. PMID: 22583117.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    Fotios's Networks
    Concepts (118)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version v3.1.0-865-g7865d7b0 on PROFILES-PWEB02.

    Copyright © The Regents of the University of California